213 related articles for article (PubMed ID: 27354181)
41. Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant.
Sloan RD; Ijaz S; Moore PL; Harrison TJ; Teo CG; Tedder RS
Antivir Ther; 2008; 13(3):439-47. PubMed ID: 18572757
[TBL] [Abstract][Full Text] [Related]
42. Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe.
Colagrossi L; Hermans LE; Salpini R; Di Carlo D; Pas SD; Alvarez M; Ben-Ari Z; Boland G; Bruzzone B; Coppola N; Seguin-Devaux C; Dyda T; Garcia F; Kaiser R; Köse S; Krarup H; Lazarevic I; Lunar MM; Maylin S; Micheli V; Mor O; Paraschiv S; Paraskevis D; Poljak M; Puchhammer-Stöckl E; Simon F; Stanojevic M; Stene-Johansen K; Tihic N; Trimoulet P; Verheyen J; Vince A; Lepej SZ; Weis N; Yalcinkaya T; Boucher CAB; Wensing AMJ; Perno CF; Svicher V;
BMC Infect Dis; 2018 Jun; 18(1):251. PubMed ID: 29859062
[TBL] [Abstract][Full Text] [Related]
43. Overlapping gene mutations of hepatitis B virus in a chronic hepatitis B patient with hepatitis B surface antigen loss during lamivudine therapy.
Lee SY; Choi MS; Lee D; Lee JH; Koh KC; Paik SW; Yoo BC
J Korean Med Sci; 2005 Jun; 20(3):433-7. PubMed ID: 15953865
[TBL] [Abstract][Full Text] [Related]
44. Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA study.
Peters L; Mocroft A; Grint D; Moreno S; Calmy A; Jevtovic D; Sambatakou H; Lacombe K; De Wit S; Rockstroh J; Smidt J; Karpov I; Grzeszczuk A; Haziosmanovic V; Gottfredsson M; Radoi R; Kuzovatova E; Orkin C; Ridolfo AL; Zapirain J; Lundgren J
Antivir Ther; 2018; 23(5):405-413. PubMed ID: 29303483
[TBL] [Abstract][Full Text] [Related]
45. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
[TBL] [Abstract][Full Text] [Related]
46. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
Ohkawa K; Takehara T; Kato M; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
J Infect Dis; 2008 Oct; 198(8):1150-8. PubMed ID: 18713056
[TBL] [Abstract][Full Text] [Related]
47. Predominance of Hepatitis B Virus Genotype A Among Treated HIV Infected Patients Experiencing High Hepatitis B Virus Drug Resistance in Nairobi, Kenya.
Mabeya SN; Ngugi C; Lihana RW; Khamadi SA; Nyamache AK
AIDS Res Hum Retroviruses; 2017 Sep; 33(9):966-969. PubMed ID: 28316253
[TBL] [Abstract][Full Text] [Related]
48. New amino acid changes in drug resistance sites and HBsAg in hepatitis B virus genotype H.
Fernández-Galindo DA; Sánchez-Ávila F; Bobadilla-Morales L; Gómez-Quiróz P; Bueno-Topete M; Armendáriz-Borunda J; Sánchez-Orozco LV
J Med Virol; 2015 Jun; 87(6):985-92. PubMed ID: 25732900
[TBL] [Abstract][Full Text] [Related]
49. [Patients co-infected with HIV and hepatitis-B virus (HBV): the favourable effect of lamivudine, as part of combined antiretroviral therapy, on HBV may be dependent upon the number of CD4-cells].
Smit MC; Haverkamp MH; Weersink AJ; Boucher CA; Hoepelman IM
Ned Tijdschr Geneeskd; 2004 Nov; 148(47):2330-4. PubMed ID: 15587052
[TBL] [Abstract][Full Text] [Related]
50. High Prevalence of HBV Lamivudine-Resistant Mutations in HBV/HIV Co-Infected Patients on Antiretroviral Therapy in the Area with the Highest Prevalence of HIV/HBV Co-Infection in China.
Jia HH; Li KW; Chen QY; Wang XY; Harrison TJ; Liang SJ; Yang QL; Wang C; Hu LP; Ren CC; Fang ZL
Intervirology; 2018; 61(3):123-132. PubMed ID: 30368502
[TBL] [Abstract][Full Text] [Related]
51. High frequency of complex mutational patterns in lamivudine resistant hepatitis B virus isolates.
Neumann-Fraune M; Beggel B; Pfister H; Kaiser R; Verheyen J
J Med Virol; 2013 May; 85(5):775-9. PubMed ID: 23408582
[TBL] [Abstract][Full Text] [Related]
52. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B.
Mirandola S; Campagnolo D; Bortoletto G; Franceschini L; Marcolongo M; Alberti A
J Viral Hepat; 2011 Jul; 18(7):e212-6. PubMed ID: 21692935
[TBL] [Abstract][Full Text] [Related]
53. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
Miailhes P; Trabaud MA; Pradat P; Lebouché B; Chevallier M; Chevallier P; Zoulim F; Trepo C
Clin Infect Dis; 2007 Sep; 45(5):624-32. PubMed ID: 17682999
[TBL] [Abstract][Full Text] [Related]
54. Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
Li X; Liu Y; Zhao P; Wang Y; Chen L; Xin S; Zhang XX; Xu D
Antivir Ther; 2015; 20(2):141-7. PubMed ID: 24992206
[TBL] [Abstract][Full Text] [Related]
55. Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir.
Lada O; Gervais A; Branger M; Peytavin G; Roquebert B; Collin G; Fraqueiro G; Moucari R; Leclerc L; Martinot-Peignoux M; Matheron S; Marcellin P
Antivir Ther; 2012; 17(1):61-70. PubMed ID: 22267470
[TBL] [Abstract][Full Text] [Related]
56. Overlapping structure of hepatitis B virus (HBV) genome and immune selection pressure are critical forces modulating HBV evolution.
Cento V; Mirabelli C; Dimonte S; Salpini R; Han Y; Trimoulet P; Bertoli A; Micheli V; Gubertini G; Cappiello G; Spanò A; Longo R; Bernassola M; Mazzotta F; De Sanctis GM; Zhang XX; Verheyen J; D'Arminio Monforte A; Ceccherini-Silberstein F; Perno CF; Svicher V
J Gen Virol; 2013 Jan; 94(Pt 1):143-149. PubMed ID: 23052389
[TBL] [Abstract][Full Text] [Related]
57. Influence of HIV-associated degree of immune suppression on molecular heterogeneity of hepatitis B virus among HIV co-infected patients.
Pal A; Panigrahi R; Biswas A; Datta S; Sarkar N; Guha SK; Saha B; Banerjee A; Chakrabarti S; Chakravarty R
Virology; 2013 Feb; 436(1):134-42. PubMed ID: 23228859
[TBL] [Abstract][Full Text] [Related]
58. Hepatitis B virus genetic multiplicity and the associated HBV lamivudine resistance mutations in HBV/HIV co-infection in Western Kenya: A review article.
Wandera BO; Onyango DM; Musyoki SK
Infect Genet Evol; 2022 Mar; 98():105197. PubMed ID: 34954390
[TBL] [Abstract][Full Text] [Related]
59. HBcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBV-coinfected patients on first-line therapy.
Malagnino V; Cerva C; Maffongelli G; Teti E; Foroghi Biland L; Cesta N; De Masi M; Stingone C; Armenia D; Svicher V; Salpini R; Andreoni M; Sarmati L
Sci Rep; 2019 Aug; 9(1):11942. PubMed ID: 31420570
[TBL] [Abstract][Full Text] [Related]
60. Prevalence of hepatitis B virus MHR mutations and their correlation with genotypes and antiviral therapy in chronically infected patients in Serbia.
Lazarevic I; Cupic M; Delic D; Svirtlih NS; Simonovic J; Jovanovic T
J Med Virol; 2010 Jul; 82(7):1160-7. PubMed ID: 20513079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
